Dr Andrew Zelenetz examines the various criteria used in individual patients with relapsed or treatment-refractory follicular lymphoma and how they help determine the trigger for and timing of initiating antitumor therapies. Dr Tycel Phillips expands on how applying such criteria may best guide the oncologist to choose specific treatment options, such as certain classes of currently available (FDA-approved) drugs in monotherapy or in combination, especially in a community-based clinical setting.
To sign up for our newsletter or print publications, please enter your contact information below.
